Advantages of OptiMedica’s Catalys® Precision Laser System to Be Validated
in 31 Clinical Presentations at ASCRS 2013
SUNNYVALE, Calif. -- April 17, 2013
OptiMedica Corp. has announced that its Catalys Precision Laser System will be
the subject of 31 accepted clinical presentations at the 2013 American Society
of Cataract and Refractive Surgery (ASCRS) conference, April 19 - 23, in San
Francisco. The presentations, which will include posters, courses, videos and
free papers, are expected to further substantiate Catalys’ unmatched
performance and clinical results in the field of laser cataract surgery. The
news comes just three years after OptiMedica unveiled its laser cataract
surgery program at ASCRS 2010.
At this year’s meeting, ASCRS attendees will learn from an international
roster of cataract experts with extensive experience using Catalys in clinical
practice. The presenters will explore several system-specific advantages,
*Broad inclusion criteria, even encompassing patients with glaucoma;
*Demonstrated benefit in challenging cases;
*Significant surgical advantages, such as near or complete elimination of
ultrasound energy and improved intraocular lens (IOL) positioning and
*Short learning curve; and,
*Positive impact on post-operative outcomes.
“We committed from OptiMedica’s founding in 2004 to make Catalys a platform
that delivers the highest levels of precision and performance in laser
cataract surgery. Today, cataract surgeons from around the world are
indicating that we have achieved our goal,” said Mark J. Forchette, president
and chief executive officer of OptiMedica. “The level of interest and
responsiveness we have seen from the surgical community – both in the ways
they are using Catalys, as well as their interest in conducting studies to
explore its advantages – is immensely gratifying. Together, we are
transforming the practice of cataract surgery for the benefit of patients
across the world.”
William Culbertson, MD, is theProfessor of Ophthalmology,The Lou Higgins
Distinguished Chair in Ophthalmology atBascom Palmer Eye Institute,Miller
School of Medicine, University of Miami; the chair of OptiMedica’s medical
advisory board; and one of a rapidly growing number of Catalys users in 12
countries around the world. At ASCRS, he will be reporting on the Catalys
system’s ability to perform precise intrastromal and anterior penetrating
arcuate incisions during the laser cataract procedure.
“Catalys was built from day one specifically for cataract surgery, and it
makes the procedure both ultra-precise and very intuitive for both surgeons
and technicians,” Dr. Culbertson said. “Having been part of the product’s
development with OptiMedica, I can speak first hand to how the team tirelessly
iterated to develop a system that was dependable, safe, and comfortably usable
even by someone not familiar with femtosecond lasers. The system simply
The ASCRS 2013 presentations are part of a growing body of peer-reviewed
literature demonstrating the key benefits that Catalys brings to laser
cataract surgery. A full schedule of all 31 ASCRS presentations can be found
Catalys is a precision laser cataract surgery platform that delivers gentle,
highly customized procedures with best-in-class accuracy and performance^1-3.
Catalys is the only laser platform designed specifically for laser cataract
surgery, and it offers several unique benefits for surgeons and patients,
including: complete capsulotomies and precision within 30 μm ^1,2; lens
fragmentation that segments and softens the cataract, enabling near
elimination of ultrasound energy in cataracts of all grades ^4,5; and, custom
corneal incision architecture based on anatomical landmarks. Key proprietary
features of the system include a Liquid Optics™ Interface that ensures gentle
docking with minimal intraocular pressure rise and clear optics for
unsurpassed imaging and laser delivery; and Integral Guidance™, 3D Full Volume
Optical Coherence Tomography (OCT) and automated surface mapping algorithms
that guide laser delivery. Since its international launch, Catalys has been
named one of the top medical technology products in the world. In 2012, the
system won the prestigious R&D 100 award from R&D Magazine and was also a
finalist in the Medical Design Excellence Awards.
Founded in 2004 and headquartered in Sunnyvale, Calif., OptiMedica Corp. is a
Silicon Valley-based global ophthalmic device company dedicated to developing
performance-driven technologies that improve patient outcomes. Exclusively
focused in the cataract therapeutic area, the company has developed the
Catalys Precision Laser System to transform existing standards of care in
cataract surgery. OptiMedica’s legacy of innovation in ophthalmology also
includes the development and commercialization of the PASCAL® Method of
retinal photocoagulation, which was acquired by Topcon Corp. in August 2010.
The company is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG
Ventures, BlackRock Private Equity Partners and Bio*One Capital. For more
information, please visit www.optimedica.com.
^1 Palanker DV, et al. “Femtosecond laser-assisted cataract surgery with
integrated optical coherence tomography.” Sci Transl Med. 2010 Nov
^2Friedman NJ, et al. “Femtosecond laser capsulotomy.” J Cataract Refract
Surg. 2011 Jul;37(7):1189-98.
^3Culbertson, B. “Optimization of corneal incision parameters with a
femtosecond laser for cataract surgery.” XXX Congress of the ESCRS, Sept.
^4Conrad-Hengerer I, Hengerer FH, Schultz T, Dick HB. “Effect of femtosecond
laser fragmentation on effective phacoemulsification time in cataract
surgery.” J Refract Surg. 2012 Dec;28(12):879-83.
^5Conrad-Hengerer I, Hengerer FH, Schultz T, Dick HB. “Effect of femtosecond
laser fragmentation of the nucleus with different softening grid sizes on
effective phaco time in cataract surgery.” J Cataract Refract Surg. 2012 Nov;
Nobles Global Communications
Laura Nobles, 310-795-0497
Press spacebar to pause and continue. Press esc to stop.